Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 14, 2009; 15(46): 5761-5769
Published online Dec 14, 2009. doi: 10.3748/wjg.15.5761
Published online Dec 14, 2009. doi: 10.3748/wjg.15.5761
Table 1 Geographic distribution and important clinical relevance of HBV genotypes and subgenotypes
| Genotype | Subgenotype | Geographic distribution | Important clinical relevance | Ref. |
| A | A1 | Africa | ND | [13-15] |
| A2 | Europe | Acute infection, chronicificaton, more sensitive to interferon treatment than genotype D | [11,12,47,48] | |
| A3 | West Africa | ND | [13-15] | |
| A4 | West Africa | ND | [15] | |
| A5 | West Africa | ND | [14,15] | |
| B | B1 | Japan | Fulminant hepatitis | [16] |
| B2 | Most of Asia, except Korea | Acute hepatitis, HCC in mostly those younger than 50 years | [6,10] | |
| B3 | Indonesia | ND | [17,18] | |
| B4 | Indonesia, Vietnam | ND | [18,19] | |
| B5 | Indonesia, Philippines | ND | [17,18,22] | |
| B6 | Indonesia | ND | [28] | |
| B7 | Indonesia | ND | [17,18] | |
| B8 | Indonesia | ND | [17] | |
| C | C1 | South Asia, Southern China | HCC and LC | [18] |
| C2 | Northeast Asia, China | HCC and LC mostly in those older than 50 years | [6,10] | |
| C3 | Indonesia, Oceania | ND | [18,19] | |
| C4 | Australia | ND | [19] | |
| C5 | Indonesia, Philippines | ND | [17,22] | |
| C6 | Indonesia, Philippines | ND | [17,21] | |
| C7 | Indonesia | ND | [17] | |
| C8 | Philippines | ND | [20,21] | |
| C9 | Tibet, China | ND | Unpublished | |
| D | D1 (mainly D) | Middle East, the Mediterranean area | Chronic liver disease, HCC | [13,23-25,37,81] |
| D2 | Russia, the Baltic region, India | No apparent clinical relevance | [26,32] | |
| D3 | Indonesia, India | Occult HBV infection | [17,32] | |
| D4 | Oceania | ND | [19] | |
| D5 | India | No apparent clinical relevance | [32] | |
| D6 | Indonesia | ND | [33] | |
| D7 | Tunisia | ND | [34] | |
| E | ND | Western and Central Africa | ND | [13,27,35] |
| F | F Ia | Central America | HCC | [29,36,62] |
| Chile, Alaska | ||||
| F Ib | Argentina, Japan, Venezuela, USA | |||
| F II | Brazil, Venezuela, Nicaragua | |||
| F III | Venezuela, Panama, Columbia | |||
| F IV | Argentina, Bolivia, France | |||
| G | ND | Mexico, Canada | ND | [30,31] |
| H | ND | Mexico | ND | [30] |
| I | ND | Vietnam, Laos | ND | [7,8] |
| J | ND | Japan (might be from Borneo) | HCC | [9] |
Table 2 HBV mutations associated with drug resistance
| Nucleoside analogs | Mutations in the polymerase domains (amino acids) | ||||
| A | B | C (YMDD) | D | E | |
| Lamivudine/ | - | V173L | M204I/V | - | - |
| Emtricitabine | L180M | ||||
| Adefovir | - | A181V | I233V | N236T | - |
| Entecavir | - | I169T | S202I | M250V | - |
| T184G | |||||
| Telbivudine | - | - | M204I | - | - |
| Famciclovir | - | L180M | - | - | - |
- Citation: Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol 2009; 15(46): 5761-5769
- URL: https://www.wjgnet.com/1007-9327/full/v15/i46/5761.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5761
